Tumor-infiltrating CD8+ T lymphocytes are commonly regarded as the core of cancer immunotherapy because they specifically recognize endogenous antigen peptide MHCI complex and kill tumor cells [9]. This evidence concerns the gene CD8A and neoplasm.